Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Sanchez

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
Blood Cancer Journal|December 11, 2021
Impact of COVID-19 in patients with multiple myeloma based on a global data networkJ Martinez-Lopez, G Hernandez-Ibarburu, R Alonso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2018
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingJ Zugazagoitia, I Ramos, J M Trigo, et al.
Annals of Surgical Oncology|May 22, 2019
RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity ScoreA Arjona-Sanchez, L Rodriguez-Ortiz, D Baratti, et al.
Journal of Dental Research|October 29, 2024
Oral Health Research in the WHO African Region between 2011 and 2022: A Scoping ReviewT F Labarca, D Ortuño, L Neira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialR A Soo, J-Y Han, U Dafni, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 3, 2016
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapyJ De Castro, J L González-Larriba, S Vázquez, et al.
CNS Drugs|December 21, 2017
Targeting Neuroinflammation to Treat Alzheimer's DiseaseA Ardura-Fabregat, E W G M Boddeke, A Boza-Serrano, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 10, 2017
European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromesR Knobler, P Moinzadeh, N Hunzelmann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 9, 2017
European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosisR Knobler, P Moinzadeh, N Hunzelmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2014
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studiesT Moran, J Wei, M Cobo, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Blood Cancer Journal|December 11, 2021
Impact of COVID-19 in patients with multiple myeloma based on a global data networkJ Martinez-Lopez, G Hernandez-Ibarburu, R Alonso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2018
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingJ Zugazagoitia, I Ramos, J M Trigo, et al.
Annals of Surgical Oncology|May 22, 2019
RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity ScoreA Arjona-Sanchez, L Rodriguez-Ortiz, D Baratti, et al.
Journal of Dental Research|October 29, 2024
Oral Health Research in the WHO African Region between 2011 and 2022: A Scoping ReviewT F Labarca, D Ortuño, L Neira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialR A Soo, J-Y Han, U Dafni, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 3, 2016
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapyJ De Castro, J L González-Larriba, S Vázquez, et al.
CNS Drugs|December 21, 2017
Targeting Neuroinflammation to Treat Alzheimer's DiseaseA Ardura-Fabregat, E W G M Boddeke, A Boza-Serrano, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 10, 2017
European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromesR Knobler, P Moinzadeh, N Hunzelmann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 9, 2017
European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosisR Knobler, P Moinzadeh, N Hunzelmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2014
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studiesT Moran, J Wei, M Cobo, et al.
Pageof 16